Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) Tax Provisions (2016 - 2024)

Vistagen Therapeutics (VTGN) has disclosed Tax Provisions for 13 consecutive years, with $7000.0 as the latest value for Q3 2024.

  • Quarterly Tax Provisions changed N/A to $7000.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $7000.0 through Jun 2025, up 600.0% year-over-year, with the annual reading at $7000.0 for FY2025, 75.0% up from the prior year.
  • Tax Provisions hit $7000.0 in Q3 2024 for Vistagen Therapeutics, up from $1000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $7000.0 in Q3 2024 to a low of $200.0 in Q3 2020.
  • Historically, Tax Provisions has averaged $2744.4 across 5 years, with a median of $3000.0 in 2020.
  • Biggest five-year swings in Tax Provisions: surged 83.33% in 2022 and later tumbled 45.45% in 2023.
  • Year by year, Tax Provisions stood at $200.0 in 2020, then surged by 1400.0% to $3000.0 in 2021, then surged by 83.33% to $5500.0 in 2022, then crashed by 45.45% to $3000.0 in 2023, then soared by 133.33% to $7000.0 in 2024.
  • Business Quant data shows Tax Provisions for VTGN at $7000.0 in Q3 2024, $1000.0 in Q1 2024, and $3000.0 in Q2 2023.